TEST:

ProstateNext®

ProstateNext is a 14-gene panel which offers more precision to identify and manage hereditary prostate cancer. 13 genes (excluding EPCAM) are evaluated using next-generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for the following genes: MLH1 (c.-337 to c.-194), and MSH2 (c.-318 to c.-65). Testing to be considered in case of presence of early-onset prostate cancer patients who are <50 years of age, have a personal history of prostate cancer and >1 family members with breast cancer who have <50 years of age and/or invasive ovarian cancer, have a personal history of prostate cancer and >2 family members with breast, pancreatic, or prostate cancer. This test is designed and validated to be capable of detecting >99% of described mutations in the gene(s) represented.